This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shafer, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shafer, R. W.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, April 2002, p. 247-277, Vol. 15, No. 2
0893-8512/02/$04.00+0     DOI: 10.1128/CMR.15.2.247-277.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance

Robert W. Shafer*

Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California

There are 16 approved human immunodeficiency virus type 1 (HIV-1) drugs belonging to three mechanistic classes: protease inhibitors, nucleoside and nucleotide reverse transcriptase (RT) inhibitors, and nonnucleoside RT inhibitors. HIV-1 resistance to these drugs is caused by mutations in the protease and RT enzymes, the molecular targets of these drugs. Drug resistance mutations arise most often in treated individuals, resulting from selective drug pressure in the presence of incompletely suppressed virus replication. HIV-1 isolates with drug resistance mutations, however, may also be transmitted to newly infected individuals. Three expert panels have recommended that HIV-1 protease and RT susceptibility testing should be used to help select HIV drug therapy. Although genotypic testing is more complex than typical antimicrobial susceptibility tests, there is a rich literature supporting the prognostic value of HIV-1 protease and RT mutations. This review describes the genetic mechanisms of HIV-1 drug resistance and summarizes published data linking individual RT and protease mutations to in vitro and in vivo resistance to the currently available HIV drugs.

* Mailing address: Division of Infectious Diseases, Room S-156, Stanford University Medical Center, Stanford, CA 94305. Phone (650) 725-2946. Fax: (650) 723-8596. E-mail: rshafer{at}cmgm.stanford.edu.

Clinical Microbiology Reviews, April 2002, p. 247-277, Vol. 15, No. 2
0893-8512/02/$04.00+0     DOI: 10.1128/CMR.15.2.247-277.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Fang, J., Wichroski, M. J., Levine, S. M., Baldick, C. J., Mazzucco, C. E., Walsh, A. W., Kienzle, B. K., Rose, R. E., Pokornowski, K. A., Colonno, R. J., Tenney, D. J. (2009). Ultrasensitive Genotypic Detection of Antiviral Resistance in Hepatitis B Virus Clinical Isolates. Antimicrob. Agents Chemother. 53: 2762-2772 [Abstract] [Full Text]  
  • Liu, Y., Eyal, E., Bahar, I. (2008). Analysis of correlated mutations in HIV-1 protease using spectral clustering. Bioinformatics 24: 1243-1250 [Abstract] [Full Text]  
  • Margerison, E. S., Maguire, M., Pillay, D., Cane, P., Elston, R. C. (2008). The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication. J Antimicrob Chemother 61: 786-791 [Abstract] [Full Text]  
  • Deforche, K., Camacho, R., Van Laethem, K., Lemey, P., Rambaut, A., Moreau, Y., Vandamme, A.-M. (2008). Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics 24: 34-41 [Abstract] [Full Text]  
  • Ceccherini-Silberstein, F., Svicher, V., Sing, T., Artese, A., Santoro, M. M., Forbici, F., Bertoli, A., Alcaro, S., Palamara, G., d'Arminio Monforte, A., Balzarini, J., Antinori, A., Lengauer, T., Perno, C. F. (2007). Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors. J. Virol. 81: 11507-11519 [Abstract] [Full Text]  
  • Molto, J., Santos, J. R., Negredo, E., Miranda, C., Videla, S., Clotet, B. (2007). Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice. J Antimicrob Chemother 60: 436-439 [Abstract] [Full Text]  
  • Lennerstrand, J., Chu, C. K., Schinazi, R. F. (2007). Biochemical Studies on the Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to 1-({beta}-D-Dioxolane)Thymine Triphosphate. Antimicrob. Agents Chemother. 51: 2078-2084 [Abstract] [Full Text]  
  • Deforche, K., Silander, T., Camacho, R., Grossman, Z ., Soares, M. A., Van Laethem, K., Kantor, R., Moreau, Y., Vandamme, A.-M., on behalf of the non-B Workgroup, (2006). Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance. Bioinformatics 22: 2975-2979 [Abstract] [Full Text]  
  • Svicher, V., Sing, T., Santoro, M. M., Forbici, F., Rodriguez-Barrios, F., Bertoli, A., Beerenwinkel, N., Bellocchi, M. C., Gago, F., d'Arminio Monforte, A., Antinori, A., Lengauer, T., Ceccherini-Silberstein, F., Perno, C. F. (2006). Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors. J. Virol. 80: 7186-7198 [Abstract] [Full Text]  
  • Winters, M. A., Welles, S. L., Holodniy, M. (2006). Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.. J. Virol. 80: 4196-4199 [Abstract] [Full Text]  
  • Rabinowitz, M., Myers, L., Banjevic, M., Chan, A., Sweetkind-Singer, J., Haberer, J., McCann, K., Wolkowicz, R. (2006). Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization. Bioinformatics 22: 541-549 [Abstract] [Full Text]  
  • Parkin, N. T., Gupta, S., Chappey, C., Petropoulos, C. J. (2006). The K101P and K103R/V179D Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nonnucleoside Reverse Transcriptase Inhibitors. Antimicrob. Agents Chemother. 50: 351-354 [Abstract] [Full Text]  
  • Nissley, D. V., Halvas, E. K., Hoppman, N. L., Garfinkel, D. J., Mellors, J. W., Strathern, J. N. (2005). Sensitive Phenotypic Detection of Minor Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Variants. J. Clin. Microbiol. 43: 5696-5704 [Abstract] [Full Text]  
  • Ceccherini-Silberstein, F., Gago, F., Santoro, M., Gori, C., Svicher, V., Rodriguez-Barrios, F., d'Arrigo, R., Ciccozzi, M., Bertoli, A., Monforte, A. d., Balzarini, J., Antinori, A., Perno, C.-F. (2005). High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations. J. Virol. 79: 10718-10729 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G. (2005). Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons. J Antimicrob Chemother 56: 265-269 [Abstract] [Full Text]  
  • Smith, A. J., Meyer, P. R., Asthana, D., Ashman, M. R., Scott, W. A. (2005). Intracellular Substrates for the Primer-Unblocking Reaction by Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Detection and Quantitation in Extracts from Quiescent- and Activated-Lymphocyte Subpopulations. Antimicrob. Agents Chemother. 49: 1761-1769 [Abstract] [Full Text]  
  • Svicher, V., Ceccherini-Silberstein, F., Erba, F., Santoro, M., Gori, C., Bellocchi, M. C., Giannella, S., Trotta, M. P., Monforte, A. d., Antinori, A., Perno, C. F. (2005). Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. Antimicrob. Agents Chemother. 49: 2015-2025 [Abstract] [Full Text]  
  • Nikolenko, G. N., Palmer, S., Maldarelli, F., Mellors, J. W., Coffin, J. M., Pathak, V. K. (2005). Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA 102: 2093-2098 [Abstract] [Full Text]  
  • Mo, H., Lu, L., Pithawalla, R., Kempf, D. J., Molla, A. (2004). Complementation in Cells Cotransfected with a Mixture of Wild-Type and Mutant Human Immunodeficiency Virus (HIV) Influences the Replication Capacities and Phenotypes of Mutant Variants in a Single-Cycle HIV Resistance Assay. J. Clin. Microbiol. 42: 4169-4174 [Abstract] [Full Text]  
  • Bradley, J., Gill, J., Bertelli, F., Letafat, S., Corbau, R., Hayter, P., Harrison, P., Tee, A., Keighley, W., Perros, M., Ciaramella, G., Sewing, A., Williams, C. (2004). Development and Automation of a 384-Well Cell Fusion Assay to Identify Inhibitors of CCR5/CD4-Mediated HIV Virus Entry. J Biomol Screen 9: 516-524 [Abstract]  
  • Saag, M. S., Cahn, P., Raffi, F., Wolff, M., Pearce, D., Molina, J.-M., Powderly, W., Shaw, A. L., Mondou, E., Hinkle, J., Borroto-Esoda, K., Quinn, J. B., Barry, D. W., Rousseau, F., for the FTC-301A Study Team, (2004). Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A Randomized Trial. JAMA 292: 180-189 [Abstract] [Full Text]  
  • Gonzalez, R., Masquelier, B., Fleury, H., Lacroix, B., Troesch, A., Vernet, G., Telles, J. N. (2004). Detection of Human Immunodeficiency Virus Type 1 Antiretroviral Resistance Mutations by High-Density DNA Probe Arrays. J. Clin. Microbiol. 42: 2907-2912 [Abstract] [Full Text]  
  • Zhang, H., Zhou, Y., Alcock, C., Kiefer, T., Monie, D., Siliciano, J., Li, Q., Pham, P., Cofrancesco, J., Persaud, D., Siliciano, R. F. (2004). Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1. J. Virol. 78: 1718-1729 [Abstract] [Full Text]  
  • Scudeller, L., Torti, C., Quiros-Roldan, E., Patroni, A., Lo Caputo, S., Moretti, F., Mazzotta, F., Donati, E., Vivarelli, A., Carosi, G., on behalf of the GenPheRex Group of the MASTER Coh, (2003). HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations. J Antimicrob Chemother 52: 776-781 [Abstract] [Full Text]  
  • Katzenstein, D. A. (2003). Genotype, Phenotype, and Virtual Phenotype: Who Needs What and Why?. J Int Assoc Physicians AIDS Care (Chic Ill) 2: 140-146  
  • Campo, R. E., Lichtenberger, P. N., Rosa, I., Suarez, G., Rivera, F. A., Rodriguez, A. E., Jayaweera, D. T., Wahlay, N. A., Kolber, M. A. (2003). Differences in the Frequency of Resistance to Antiretroviral Drug Classes among Human Immunodeficiency Virus Type 1 Clinical Isolates. J. Clin. Microbiol. 41: 3376-3378 [Abstract] [Full Text]  
  • Sarmati, L., Nicastri, E., Uccella, I., d'Ettorre, G., Parisi, S. G., Palmisano, L., Galluzzo, C., Concia, E., Vullo, V., Vella, S., Andreoni, M. (2003). Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing. J. Clin. Microbiol. 41: 1760-1762 [Abstract] [Full Text]  
  • Rhee, S.-Y., Gonzales, M. J., Kantor, R., Betts, B. J., Ravela, J., Shafer, R. W. (2003). Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298-303 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»